A Phase II Evaluation of AMG 102 (Rilotumumab) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

PURPOSE: This open-label, multi-institutional Phase II trial evaluated activity and safety of rilotumumab (AMG 102), a monoclonal antibody that targets HGF (hepatocyte growth factor), the ligand for the MET receptor, in women with recurrent or persistent epithelial ovarian, fallopian tube or primary...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Gynecol Oncol
Main Authors: Martin, Lainie P., Sill, Michael, Shahin, Mark S., Powell, Matthew, DiSilvestro, Paul, Landrum, Lisa M., Gaillard, Stephanie L., Goodheart, Michael J., Hoffman, James, Schilder, Russell J.
Format: Artigo
Sprog:Inglês
Udgivet: 2013
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4469031/
https://ncbi.nlm.nih.gov/pubmed/24361733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.12.018
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker